Author: Editor

Dr. Julie Brahmer, Johns Hopkins University, discusses the use of biomarker testing and mutational burden to select patients for specific immunotherapies in lung cancer, renal cell carcinoma and melanoma.

Dr. Ed Kim from the Levine Cancer Institute reviews the potential advantages and current limitations of blood-based testing for molecular markers using circulating tumor cells and circulating tumor DNA in identifying clinically important mutations.

Dr. Cathy Pietanza from Memorial Sloan Kettering Cancer Center discusses standard chemotherapy options for treatment of both sensitive and refractory small cell lung cancer (SCLC).

Dr. Cathy Pietanza from Memorial Sloan Kettering Cancer Center reviews early trial data of immunotherapy agents for treatment of small cell lung cancer (SCLC).

Dr. Edward S. Kim from the Levine Cancer Institute in Charlotte, NC defines the concept of cancer histology and gives examples of several lung cancer subtypes.

Earn CME credit for this activity: https://www.naccme.com/program/2018-802-01 With a focus on integrating recent advances into improved care pathways, this on-demand webcast features a presentation on the latest treatment options, current guidelines, available cost data, and expert recommendations. © 2018 NACCME, an HMP Company

Earn CME credit for this activity: https://www.naccme.com/program/2018-802-02 This on-demand webcast examines the efficacy and safety, indications, and cost utility of available EGFR tyrosine kinase inhibitors (TKIs) and monoclonal antibodies into optimal first-line selection and NSCLC pathway placement strategies. © 2018 NACCME, an HMP Company

Earn CME credit for this activity: https://www.naccme.com/program/2018-802-04 This on-demand webcast examines the latest clinical and pharmacoeconomic data surrounding emerging therapies in AML, including novel chemotherapy formulations, FLT3 inhibitors, and IDH inhibitors for informed pathway placement. © 2018 NACCME, an HMP Company

Earn CME credit for this activity: https://www.naccme.com/program/2018-802-03 This on-demand activity examines the implications of BRCA mutational status, BRCAness, synthetic lethality, and within-class differences in the mechanisms of action, efficacy and safety, and indications of available and emerging PARP inhibitors for optimal ovarian cancer pathway integration. © 2018 NACCME, an HMP Company

Earn CME credit for this activity: https://www.naccme.com/program/2018-802-05 This on-demand webcast examines recent clinical trial data for novel and emerging therapies, including doublet and triplet combinations for relapsed/refractory disease, and discusses how best to integrate recent therapeutic advances into clinical pathways. © 2018 NACCME, an HMP Company

Edward B. Garon, M.D., MS Associate Clinical Professor, Director Of Thoracic Oncology Program, David Geffen School Of Medicine At UCLA, Director Of Signal Transduction And Therapeutics, Jonsson Comprehensive Cancer Center At UCLA, Discusses Checkmate 227 & Keynote 042 Potential Practice Changing Approaches. At MOASC Oncology Summit On Feb 23, 2019. For More Info Visit: https://moasc.org…

Edward B. Garon, M.D., MS Associate Clinical Professor, Director Of Thoracic Oncology Program, David Geffen School Of Medicine At UCLA, Director Of Signal Transduction And Therapeutics, Jonsson Comprehensive Cancer Center At UCLA, Discusses Have Advances In NSCLC Extended To The Elderly. At MOASC Oncology Summit On Feb 23, 2019. For More Info Visit: https://moasc.org

Robert Depriest, PharmD MBA Regional Sales Director At Walgreens, Discusses How To Participate In “Feel More Like You”. At MOASC Oncology Summit On Feb 23, 2019. For More Info Visit: https://moasc.org

Robert Depriest, PharmD MBA Regional Sales Director At Walgreens, Discusses Benefits Of “Feel More Like You” Program. At MOASC Oncology Summit On Feb 23, 2019. For More Info Visit: https://moasc.org

Robert Depriest, PharmD MBA Regional Sales Director At Walgreens, Discusses “Feel More Like You” Program. At MOASC Oncology Summit On Feb 23, 2019. For More Info Visit: https://moasc.org

Andrew Hendifar M.D. Medical Director, Pancreatic Cancer Assistant Professor, Medicine At Cedars-Sinai, Discusses Personalized Medicine In Pancreas Cancer. At MOASC Oncology Summit On Feb 23, 2019. For More Info Visit: https://moasc.org

Andrew Hendifar M.D. Medical Director, Pancreatic Cancer Assistant Professor, Medicine At Cedars-Sinai, Discusses Know Your Tumor Initiative. At MOASC Oncology Summit On Feb 23, 2019. For More Info Visit: https://moasc.org

Andrew Hendifar M.D. Medical Director, Pancreatic Cancer Assistant Professor, Medicine At Cedars-Sinai, Discusses Evolution Of Pancreatic Cancer Treatment. At MOASC Oncology Summit On Feb 23, 2019. For More Info Visit: https://moasc.org

Andrew Hendifar M.D. Medical Director, Pancreatic Cancer Assistant Professor, Medicine At Cedars-Sinai, Discusses Elaborating On Pancreas Cancer. At MOASC Oncology Summit On Feb 23, 2019. For More Info Visit: https://moasc.org

Gary Schiller, M.D. Professor of Medicine Division of Hematology/Oncology At UCLA, Discusses Whats New In AML Transplants. At MOASC Oncology Summit On Feb 23, 2019. For More Info Visit: https://moasc.org

Gary Schiller, M.D. Professor of Medicine Division of Hematology/Oncology At UCLA, Discusses Strategies To Treat AML. At MOASC Oncology Summit On Feb 23, 2019. For More Info Visit: https://moasc.org

Gary Schiller, M.D. Professor of Medicine Division of Hematology/Oncology At UCLA, Discusses Elaborating On Drug Approvals In AML. At MOASC Oncology Summit On Feb 23, 2019. For More Info Visit: https://moasc.org

Gary Schiller, M.D. Professor of Medicine Division of Hematology/Oncology At UCLA, Discusses Approaches Seen In AML. At MOASC Oncology Summit On Feb 23, 2019. For More Info Visit: https://moasc.org

Amrita Krishnan, M.D. Director of the Judy and Bernard Briskin Center for Multiple Myeloma Research Director, Multiple Myeloma Program Associate Director, Medical Education & Training Program Professor, Department of Hematology & Hematopoietic Cell Transplantation, City Of Hope, Discusses The Future Of Myeloma Treatment. At MOASC Oncology Summit On Feb 23, 2019. For More Info Visit: https://moasc.org

Amrita Krishnan, M.D. Director of the Judy and Bernard Briskin Center for Multiple Myeloma Research Director, Multiple Myeloma Program Associate Director, Medical Education & Training Program Professor, Department of Hematology & Hematopoietic Cell Transplantation, City Of Hope, Discusses Details On The SWOG1803 Trial. At MOASC Oncology Summit On Feb 23, 2019. For More Info Visit: https://moasc.org

Amrita Krishnan, M.D. Director of the Judy and Bernard Briskin Center for Multiple Myeloma Research Director, Multiple Myeloma Program Associate Director, Medical Education & Training Program Professor, Department of Hematology & Hematopoietic Cell Transplantation, City Of Hope, Discusses Updates On CAR-T Therapy In Myeloma. At MOASC Oncology Summit On Feb 23, 2019. For More Info Visit: https://moasc.org

Amrita Krishnan, M.D. Director of the Judy and Bernard Briskin Center for Multiple Myeloma Research Director, Multiple Myeloma Program Associate Director, Medical Education & Training Program Professor, Department of Hematology & Hematopoietic Cell Transplantation, City Of Hope, Discusses Monoclonal Antibodies In Myeloma Therapy. At MOASC Oncology Summit On Feb 23, 2019. For More Info Visit: https://moasc.org

Amrita Krishnan, M.D. Director of the Judy and Bernard Briskin Center for Multiple Myeloma Research Director, Multiple Myeloma Program Associate Director, Medical Education & Training Program Professor, Department of Hematology & Hematopoietic Cell Transplantation, City Of Hope, Discusses Data Regarding MAIA Trial & Treating Myeloma. At MOASC Oncology Summit On Feb 23, 2019. For More Info Visit: https://moasc.org……

William Dale, M.D., PhD Professor & Arthur Coppola Family Chair, Department Of Supportive Care Medicine, City of Hope, Discusses The Importance of Palliative Care. At MOASC Oncology Summit On Feb 23, 2019. For More Info Visit: https://moasc.org…

William Dale, M.D., PhD Professor & Arthur Coppola Family Chair, Department Of Supportive Care Medicine, City of Hope, Discusses The Importance Of Measuring Gate Speed. At MOASC Oncology Summit On Feb 23, 2019. For More Info Visit: https://moasc.org…

William Dale, M.D., PhD Professor & Arthur Coppola Family Chair, Department Of Supportive Care Medicine, City of Hope, Discusses The Geriatric Standard Assessment. At MOASC Oncology Summit On Feb 23, 2019. For More Info Visit: https://moasc.org…

William Dale, M.D., PhD Professor & Arthur Coppola Family Chair, Department Of Supportive Care Medicine, City of Hope, Discusses Mental Health Care For Cancer Patients. At MOASC Oncology Summit On Feb 23, 2019. For More Info Visit: https://moasc.org…

William Dale, M.D., PhD Professor & Arthur Coppola Family Chair, Department Of Supportive Care Medicine, City of Hope, Discusses Medical Health Vs Comprehensive Health. At MOASC Oncology Summit On Feb 23, 2019. For More Info Visit: https://moasc.org…

William Dale, M.D., PhD Professor & Arthur Coppola Family Chair, Department Of Supportive Care Medicine, City of Hope, Discusses Insight Into Geriatric Assessments. At MOASC Oncology Summit On Feb 23, 2019. For More Info Visit: https://moasc.org…

William Dale, M.D., PhD Professor & Arthur Coppola Family Chair, Department Of Supportive Care Medicine, City of Hope, Discusses Details Regarding Palliative Care Study. At MOASC Oncology Summit On Feb 23, 2019. For More Info Visit: https://moasc.org…

Edward B. Garon, M.D., MS Associate Clinical Professor, Director Of Thoracic Oncology Program, David Geffen School Of Medicine At UCLA, Director Of Signal Transduction And Therapeutics, Jonsson Comprehensive Cancer Center At UCLA, Discusses Lung Cancer (With Focus On Elderly). Dr. Garon Elaborates On The ECOG 4599 Trial Looking At Paclitaxel & Carboplatin + Bevacizumab In First Line NSCLC & The Efficacy Of Nivolumab Monotherapy. He Also Discusses The SWOG 9504 Trial Looking At Docetaxel After Concurrent Chemoradiotherapy And How It Did Much Better Then Historical Controls. This Was All discussed At MOASC Oncology Summit On Feb 23, 2019. For More…

Andrew Hendifar, M.D. Medical Director, Pancreatic Cancer Cedars-Sinai Medical Center, Discusses Personalized Therapy For Pancreas Cancer: Have We Arrived? Dr. Hendifar elaborates On Pancreatic Cancer, Its Increasing Risk To Society, & How To Treat It As Best As We Can Today. Projections Show Pancreatic Cancer Becoming The Second Leading Cause Of Cancer-Related Death By 2030, Dr Hendifar Discusses A Personalized Approach To Treating This Disease Focusing On Germline Variation To Develop A Treatment Plan For The Difficult Malignancy. This Was All Discussed At MOASC Oncology Summit On Feb 23, 2019. For More Info Visit: https://moasc.org…

Amrita Krishnan, M.D. Director of the Judy and Bernard Briskin Center for Multiple Myeloma Research Director, Multiple Myeloma Program Associate Director, Medical Education & Training Program Professor, Department of Hematology & Hematopoietic Cell Transplantation, City Of Hope, Discusses Myeloma In 2019 Including The SWOG s1803 Trial And Data. Dr. Krishnan Discusses Where The Myeloma Field Is Going For Example Higher Efficacy, Minimize long term toxicities, & MRD-Driven Therapy. She Discusses If You Should Use The Best Available Therapies Upfront Or Save The Best For Later And Even Dives Into The Maia Trial Design. This Was All discussed At MOASC Oncology…

William Dale, M.D., PhD Professor & Arthur Coppola Family Chair, Department Of Supportive Care Medicine, City of Hope, Discusses Comprehensive Care For Older Adults With Cancer – Integrating Supportive Care With Geriatrics. Dr. Dale Also Dives Into Important Questions like Who Benefits From Palliative Care? Who Benefits From Geriatrics? What Is Comprehensive Health? What Is A Comprehensive Integrated Supportive Care Approach? Palliative Care Is Very Important To Dr. Dale, Knowing And Understanding The Full Spectrum Of A Patients Health Is Critical To A Successful Treatment. This Was All discussed At MOASC Oncology Summit On Feb 23, 2019. For More Info…

John Strickler, M.D. Assistant Professor Of Medicine At Duke Cancer Institute, Discusses Comprehensive Genomic Profiling Of Pancreatic Cancer. At The 2019 Gastrointestinal Cancers Symposium In San Francisco, CA On Jan 17, 2019. http://obroncology.com

John Strickler, M.D. Assistant Professor Of Medicine At Duke Cancer Institute, Discusses The Importance Of Genomic Profiling In Treating Colorectal Cancer. At The 2019 Gastrointestinal Cancers Symposium In San Francisco, CA On Jan 17, 2019. http://obroncology.com

John Strickler, M.D. Assistant Professor Of Medicine At Duke Cancer Institute, Discusses KEYNOTE-181 Esophageal Cancer Study. At The 2019 Gastrointestinal Cancers Symposium In San Francisco, CA On Jan 17, 2019. http://obroncology.com

Ghassan Abou-Alfa, M.D. Attending Physician At Memorial Sloan Kettering Cancer Center, Discusses Embolization Therapy For Liver Cancer. At The 2019 Gastrointestinal Cancers Symposium In San Francisco, CA On Jan 17, 2019. http://obroncology.com

Ghassan Abou-Alfa, M.D. Attending Physician At Memorial Sloan Kettering Cancer Center, Discusses Data On Combining TKIs & Checkpoint Inhibitors In The Treatment Of Liver Cancer. At The 2019 Gastrointestinal Cancers Symposium In San Francisco, CA On Jan 17, 2019. http://obroncology.com

Ghassan Abou-Alfa, M.D. Attending Physician At Memorial Sloan Kettering Cancer Center, Discusses Checkpoint Inhibitors In The Treatment Of Liver Cancer. At The 2019 Gastrointestinal Cancers Symposium In San Francisco, CA On Jan 17, 2019. http://obroncology.com

Ghassan Abou-Alfa, M.D. Attending Physician At Memorial Sloan Kettering Cancer Center Discusses, New Therapies In The Treatment Of Liver Cancer. At The 2019 Gastrointestinal Cancers Symposium In San Francisco, CA On Jan 17, 2019. http://obroncology.com

Bassel El-Rayes, M.D. Professor & Vice Chair For Clinical Research, Department Of Hematology & Medical Oncology Emory University School Of Medicine, John Kauffman Family Professor For Pancreatic Cancer Research Associate Director For Clinical Research, Director Of The Gastrointestinal Oncology Program Winship Cancer Institute Of Emory University Discusses PARP Inhibitors & PEGPH20 Stroma Disrupting Agents. At The 2019 Gastrointestinal Cancers Symposium In San Francisco, CA On Jan 17, 2019. http://obroncology.com

Bassel El-Rayes, M.D. Professor & Vice Chair For Clinical Research, Department Of Hematology & Medical Oncology Emory University School Of Medicine, John Kauffman Family Professor For Pancreatic Cancer Research Associate Director For Clinical Research, Director Of The Gastrointestinal Oncology Program Winship Cancer Institute Of Emory University Discusses Advantages With Upfront Chemotherapy. At The 2019 Gastrointestinal Cancers Symposium In San Francisco, CA On Jan 17, 2019. http://obroncology.com

Bassel El-Rayes, M.D. Professor & Vice Chair For Clinical Research, Department Of Hematology & Medical Oncology Emory University School Of Medicine, John Kauffman Family Professor For Pancreatic Cancer Research Associate Director For Clinical Research, Director Of The Gastrointestinal Oncology Program Winship Cancer Institute Of Emory University Discusses Everybody With Pancreatic Cancer Recommended To Get BRCA Testing. At The 2019 Gastrointestinal Cancers Symposium In San Francisco, CA On Jan 17, 2019. http://obroncology.com

Bassel El-Rayes, M.D. Professor & Vice Chair For Clinical Research, Department Of Hematology & Medical Oncology Emory University School Of Medicine, John Kauffman Family Professor For Pancreatic Cancer Research Associate Director For Clinical Research, Director Of The Gastrointestinal Oncology Program Winship Cancer Institute Of Emory University Discusses Good News In Pancreatic Cancer. At The 2019 Gastrointestinal Cancers Symposium In San Francisco, CA On Jan 17, 2019. http://obroncology.com

Martine Extermann, M.D. Program Leader In The Senior Adult Oncology Program, Moffit Cancer Center, Discusses The Importance Of Precision Medicine In Gastric Cancers. At The 2019 Gastrointestinal Cancers Symposium In San Francisco, CA On Jan 17, 2019. http://obroncology.com

Martine Extermann, M.D. Program Leader In The Senior Adult Oncology Program, Moffit Cancer Center, Discusses Elderly Patients Benefit From Third Line Metastatic Gastric Cancer Study. At The 2019 Gastrointestinal Cancers Symposium In San Francisco, CA On Jan 17, 2019. http://obroncology.com

Martine Extermann, M.D. Program Leader In The Senior Adult Oncology Program, Moffit Cancer Center, Discusses Thoughts On Third Line Study For Metastatic Gastric Cancer. At The 2019 Gastrointestinal Cancers Symposium In San Francisco, CA On Jan 17, 2019. http://obroncology.com

Raymond Wadlow, M.D. Medical Oncologist At Inova Fairfax Hospital Discusses Correlation Between Modified Resist Criteria In HCC & Overall Survival In REFLECT Study. At The 2019 Gastrointestinal Cancers Symposium In San Francisco, CA On Jan 17, 2019. http://obroncology.com

Raymond Wadlow, M.D. Medical Oncologist At Inova Fairfax Hospital Discusses REFLECT Phase 3 Study Utilizing Lenvatinib & Recent Approval Of Cabozantinib. At The 2019 Gastrointestinal Cancers Symposium In San Francisco, CA On Jan 17, 2019. http://obroncology.com

Raymond Wadlow, M.D. Medical Oncologist At Inova Fairfax Hospital Discusses Thoughts On CCTG CO.26 Canadian Study Demonstrating Immunotherapy Benefit In Colorectal Cancer. At The 2019 Gastrointestinal Cancers Symposium In San Francisco, CA On Jan 17, 2019. http://obroncology.com

Raymond Wadlow, M.D. Medical Oncologist At Inova Fairfax Hospital Discusses Data On KETNOTE-181 Esophageal Cancer Study Utilizing Pembrolizumab. At The 2019 Gastrointestinal Cancers Symposium In San Francisco, CA On Jan 17, 2019. http://obroncology.com

Zev Wainberg, M.D. Co-Director UCLA Gastro-Intestinal Oncology Program, Medical Director, UCLA Colorectal Hematology Oncology David Geffen School Of Medicine At UCLA Discusses Data On Debrafenib & Trametinib Combo Therapy Study Testing For BRAFV600E Mutation. At The 2019 Gastrointestinal Cancers Symposium In San Francisco, CA On Jan 17, 2019.

Zev Wainberg, M.D. Co-Director UCLA Gastro-Intestinal Oncology Program, Medical Director, UCLA Colorectal Hematology Oncology David Geffen School Of Medicine At UCLA Discusses REACHIN Study Using Regorafenib In Biliary Tract Cancer. At The 2019 Gastrointestinal Cancers Symposium In San Francisco, CA On Jan 17, 2019. http://obroncology.com

Zev Wainberg, M.D. Co-Director UCLA Gastro-Intestinal Oncology Program, Medical Director, UCLA Colorectal Hematology Oncology David Geffen School Of Medicine At UCLA Discusses Data Regarding Abraxane, Gemcitabine Plus Nivolumab Combo Study In Pancreatic Cancer. At The 2019 Gastrointestinal Cancers Symposium In San Francisco, CA On Jan 17, 2019. http://obroncology.com

Richard Finn, MD Professor of Clinical Medicine, Department of Medicine, Division of Hematology/ Oncology, Geffen School of Medicine, UCLA discusses The Role Of TACE With Systemic Therapy In HCC. At The 2019 Gastrointestinal Cancers Symposium In San Francisco, CA On Jan 17, 2019. http://obroncology.com

Richard Finn, MD Professor of Clinical Medicine, Department of Medicine, Division of Hematology/ Oncology, Geffen School of Medicine, UCLA discusses The Effectiveness Of Sorafenib In Newly Diagnosed HCC. At The 2019 Gastrointestinal Cancers Symposium In San Francisco, CA On Jan 17, 2019. http://obroncology.com

Richard Finn, MD Professor of Clinical Medicine, Department of Medicine, Division of Hematology/ Oncology, Geffen School of Medicine, UCLA discusses Current Treatment Options & Sequencing Of TKIs In HCC. At The 2019 Gastrointestinal Cancers Symposium In San Francisco, CA On Jan 17, 2019. http://obroncology.com

David Ilson, MD, PhD Attending Physician, Memorial Sloan Kettering Cancer Center, Professor of Medicine, Weill Cornell Medical College, Discusses The Use Of Biomarkers In The Treatment Of Esophagogastric Cancer. At The 2019 Gastrointestinal Cancers Symposium In San Francisco, CA On Jan 17, 2019. http://obroncology.com

David Ilson, MD, PhD Attending Physician, Memorial Sloan Kettering Cancer Center, Professor of Medicine, Weill Cornell Medical College, Discusses The Role Of I-O In Esophagogastric Cancer Treatment Algorithms. At The 2019 Gastrointestinal Cancers Symposium In San Francisco, CA On Jan 17, 2019. http://obroncology.com

David Ilson, MD, PhD Attending Physician, Memorial Sloan Kettering Cancer Center, Professor of Medicine, Weill Cornell Medical College, Discusses Pembrolizumab, Trastuzumab, Capecitabine & Oxaliplatin In HER2+ mEGA. At The 2019 Gastrointestinal Cancers Symposium In San Francisco, CA On Jan 17, 2019. http://obroncology.com

Dr. Edward S. Kim from the Levine Cancer Institute in Charlotte, NC describes the use of serum tumor markers in various types of cancer, and the lack of a useful serum tumor marker in lung cancer.

Dr. Jeffrey Bradley, Radiation Oncologist at Washington University in St. Louis, provides evidence for the use of stereotactic body radiation therapy as an alternative to surgery for operable early stage lung cancer.

Dr. Edward S. Kim from the Levine Cancer Institute in Charlotte, NC discusses the feasibility of molecular marker testing and targeted therapy in the adjuvant or post-operative setting.

Howard Hochster, MD, Associate Director for Clinical Research, Rutgers Cancer institute of New jersey, Director of Oncology Research, RWJBarnabas Health discusses, How Checkpoint Inhibitors Are Impacting Treatment Algorithms In mCRC. At The 2019 Gastrointestinal Cancers Symposium In San Francisco, CA On Jan 17, 2019. http://obroncology.com

Howard Hochster, MD, Associate Director for Clinical Research, Rutgers Cancer institute of New jersey, Director of Oncology Research, RWJBarnabas Health discusses, Next Generation Sequencing And mCRC Treatment Decisions. At The 2019 Gastrointestinal Cancers Symposium In San Francisco, CA On Jan 17, 2019. http://obroncology.com

Howard Hochster, MD, Associate Director for Clinical Research, Rutgers Cancer institute of New jersey, Director of Oncology Research, RWJBarnabas Health discusses, The Management Of mCRC Patients Receiving Regorafenib. At The 2019 Gastrointestinal Cancers Symposium In San Francisco, CA On Jan 17, 2019. http://obroncology.com

Howard Hochster, MD, Associate Director for Clinical Research, Rutgers Cancer institute of New jersey, Director of Oncology Research, RWJBarnabas Health discusses, The Role Of Genetic Testing In mCRC. At The 2019 Gastrointestinal Cancers Symposium In San Francisco, CA On Jan 17, 2019. http://obroncology.com

Howard Hochster, MD, Associate Director for Clinical Research, Rutgers Cancer institute of New jersey, Director of Oncology Research, RWJBarnabas Health discusses, How To Manage 2nd And 3rd Line mCRC Patients. At The 2019 Gastrointestinal Cancers Symposium In San Francisco, CA On Jan 17, 2019. http://obroncology.com

Jeffrey A. Meyerhardt, MD, Professor, Medicine, Harvard Medical School Active Medical Staff, Medical Oncology, Dana-Farber Cancer Institute discusses, Whether Regorafenib Is Becoming More Tolerable For mCRC Patients. At The 2019 Gastrointestinal Cancers Symposium In San Francisco, CA On Jan 17, 2019. http://obroncology.com

Jeffrey A. Meyerhardt, MD, Professor, Medicine, Harvard Medical School Active Medical Staff, Medical Oncology, Dana-Farber Cancer Institute discusses, Genetic Testing In Newly Diagnosed mCRC. At The 2019 Gastrointestinal Cancers Symposium In San Francisco, CA On Jan 17, 2019. http://obroncology.com

Jeffrey A. Meyerhardt, MD, Professor, Medicine, Harvard Medical School Active Medical Staff, Medical Oncology, Dana-Farber Cancer Institute discusses, Thoughts On Checkpoint Inhibitors In Adjuvant CRC. At The 2019 Gastrointestinal Cancers Symposium In San Francisco, CA On Jan 17, 2019. http://obroncology.com

Jeffrey A. Meyerhardt, MD, Professor, Medicine, Harvard Medical School Active Medical Staff, Medical Oncology, Dana-Farber Cancer Institute discusses, Managing 2nd And 3rd Line mCRC Patients. At The 2019 Gastrointestinal Cancers Symposium In San Francisco, CA On Jan 17, 2019. http://obroncology.com

Jeffrey A. Meyerhardt, MD, Professor, Medicine, Harvard Medical School Active Medical Staff, Medical Oncology, Dana-Farber Cancer Institute discusses, BEACON Study In BRAF Mutated Metastatic Colorectal Cancer. At The 2019 Gastrointestinal Cancers Symposium In San Francisco, CA On Jan 17, 2019. http://obroncology.com

Nevena Damjanov, MD, Chief of GI Oncology, Abramson Cancer Center at Penn Presbyterian, University of Pennsylvania discusses, The Impact Of The ReDOS study In HCC. At The 2019 Gastrointestinal Cancers Symposium In San Francisco, CA On Jan 17, 2019. http://obroncology.com

Nevena Damjanov, MD, Chief of GI Oncology, Abramson Cancer Center at Penn Presbyterian, University of Pennsylvania discusses, Sequencing TKIs In Hepatocellular Carcinoma (HCC). At The 2019 Gastrointestinal Cancers Symposium In San Francisco, CA On Jan 17, 2019. http://obroncology.com

Nevena Damjanov, MD, Chief of GI Oncology, Abramson Cancer Center at Penn Presbyterian, University of Pennsylvania discusses, Thoughts On The Role Of Systemic Therapy In HCC. At The 2019 Gastrointestinal Cancers Symposium In San Francisco, CA On Jan 17, 2019. http://obroncology.com

Nevena Damjanov, MD, Chief of GI Oncology, Abramson Cancer Center at Penn Presbyterian, University of Pennsylvania discusses, Stereotactic Body Radiation Therapy In Early Stage HCC. At The 2019 Gastrointestinal Cancers Symposium In San Francisco, CA On Jan 17, 2019. http://obroncology.com

Philip Philip MD, PhD, FRCP, Professor of Oncology, Wayne State University School of Medicine, Clinical Professor of Oncology, Barbara Ann Karmanos Cancer Institute, Discusses Screening Patients At High Risk For Pancreatic Cancer. At The 2019 Gastrointestinal Cancers Symposium In San Francisco, CA On Jan 17, 2019. http://obroncology.com

Philip Philip MD, PhD, FRCP, Professor of Oncology, Wayne State University School of Medicine, Clinical Professor of Oncology, Barbara Ann Karmanos Cancer Institute, Discusses Opinion On NGS And BRCA Gene Testing In Pancreatic Cancer. At The 2019 Gastrointestinal Cancers Symposium In San Francisco, CA On Jan 17, 2019. http://obroncology.com

Philip Philip MD, PhD, FRCP, Professor of Oncology, Wayne State University School of Medicine, Clinical Professor of Oncology, Barbara Ann Karmanos Cancer Institute, Discusses Neoadjuvant Chemotherapy & Upfront Surgery In Pancreatic Cancer. At The 2019 Gastrointestinal Cancers Symposium In San Francisco, CA On Jan 17, 2019. http://obroncology.com

Philip Philip MD, PhD, FRCP, Professor of Oncology, Wayne State University School of Medicine, Clinical Professor of Oncology, Barbara Ann Karmanos Cancer Institute, Discusses Promising Novel Therapies For Pancreatic Cancer. At The 2019 Gastrointestinal Cancers Symposium In San Francisco, CA On Jan 17, 2019. http://obroncology.com

Philip Philip MD, PhD, FRCP, Professor of Oncology, Wayne State University School of Medicine, Clinical Professor of Oncology, Barbara Ann Karmanos Cancer Institute, Discusses Molecular SubTyping Of Pancreatic Cancer. At The 2019 Gastrointestinal Cancers Symposium In San Francisco, CA On Jan 17, 2019. http://obroncology.com

Axel Grothey, MD, Consultant, West Cancer Center, University of Tennessee, Discusses The Use Of Regorafenib In The Management Of Advanced CRC. At The 2019 Gastrointestinal Cancers Symposium In San Francisco, CA On Jan 17, 2019. http://obroncology.com

Axel Grothey, MD, Consultant, West Cancer Center, University of Tennessee, Discusses Patient Selection & Treatment Algorithms In 2nd And 3rd Line CRC. At The 2019 Gastrointestinal Cancers Symposium In San Francisco, CA On Jan 17, 2019. http://obroncology.com

Axel Grothey, MD, Consultant, West Cancer Center, University of Tennessee, Discusses The Role Of Circulating Tumor DNA (ctDNA). At The 2019 Gastrointestinal Cancers Symposium In San Francisco, CA On Jan 17, 2019. http://obroncology.com

Axel Grothey, MD, Consultant, West Cancer Center, University of Tennessee, Discusses CCTG CO.26 Trial In Advanced Refractory CRC Presented At GI 2019. At The 2019 Gastrointestinal Cancers Symposium In San Francisco, CA On Jan 17, 2019. http://obroncology.com

Axel Grothey, MD, Consultant, West Cancer Center, University of Tennessee, Discusses Next Generation Sequencing And mCRC. At The 2019 Gastrointestinal Cancers Symposium In San Francisco, CA On Jan 17, 2019. http://obroncology.com

Alan Venook, MD, Shorenstein Associate Director for Program Development, Helen Diller Family Comprehensive Cancer Center, Professor, Department of Medicine, UCSF, Discusses The Latest In Identifying Valid Biomarkers In The Treatment Of HCC. At The 2019 Gastrointestinal Cancers Symposium In San Francisco, CA On Jan 17, 2019.

Alan Venook, MD, Shorenstein Associate Director for Program Development, Helen Diller Family Comprehensive Cancer Center, Professor, Department of Medicine, UCSF, Discusses Key Takeaways From GI 2019 Regarding The Treatment Of Biliary Tract Cancers. At The 2019 Gastrointestinal Cancers Symposium In San Francisco, CA On Jan 17, 2019.

Alan Venook, MD, Shorenstein Associate Director for Program Development, Helen Diller Family Comprehensive Cancer Center, Professor, Department of Medicine, UCSF, Discusses Next Generation Sequencing And mCRC Treatment. At The 2019 Gastrointestinal Cancers Symposium In San Francisco, CA On Jan 17, 2019.

Alan Venook, MD, Shorenstein Associate Director for Program Development, Helen Diller Family Comprehensive Cancer Center, Professor, Department of Medicine, UCSF, Discusses Is ctDNA Is A Valid Treatment Response In CRC. At The 2019 Gastrointestinal Cancers Symposium In San Francisco, CA On Jan 17, 2019.

David Ilson, MD, PhD Attending Physician, Memorial Sloan Kettering Cancer Center, Professor of Medicine, Weill Cornell Medical College, Discusses Pembrolizumab & Chemotherapy In Advanced Esophageal Cancer. At The 2019 Gastrointestinal Cancers Symposium In San Francisco, CA On Jan 17, 2019. http://obroncology.com

David Ilson, MD, PhD Attending Physician, Memorial Sloan Kettering Cancer Center, Professor of Medicine, Weill Cornell Medical College, Discusses Results From The TAGS Trial Presented At GI 2019. At The 2019 Gastrointestinal Cancers Symposium In San Francisco, CA On Jan 17, 2019. http://obroncology.com

Rachna Shroff, MD Chief, Section of GI Medical Oncology, Associate Professor of Medicine, Division of Hematology/Oncology, University of Arizona Cancer Center, discusses Targeted Therapies In The Treatment Of Cholangiocarcinoma. At The 2019 Gastrointestinal Cancers Symposium In San Francisco, CA On Jan 17, 2019. http://obroncology.com

Rachna Shroff, MD Chief, Section of GI Medical Oncology, Associate Professor of Medicine, Division of Hematology/Oncology, University of Arizona Cancer Center, discusses How BRAF Mutations Figure Into Cholangiocarcinoma Treatment. At The 2019 Gastrointestinal Cancers Symposium In San Francisco, CA On Jan 17, 2019. http://obroncology.com

Rachna Shroff, MD Chief, Section of GI Medical Oncology, Associate Professor of Medicine, Division of Hematology/Oncology, University of Arizona Cancer Center, discusses The Utilization Of TKIs In Treatment Of Hepatocellular Carcinoma. At The 2019 Gastrointestinal Cancers Symposium In San Francisco, CA On Jan 17, 2019. http://obroncology.com

Rachna Shroff, MD Chief, Section of GI Medical Oncology, Associate Professor of Medicine, Division of Hematology/Oncology, University of Arizona Cancer Center, discusses Pre-Operative Therapy In Resectable Pancreatic Cancer. At The 2019 Gastrointestinal Cancers Symposium In San Francisco, CA On Jan 17, 2019. http://obroncology.com

Andrew X. Zhu, MD, PhD Associate Professor, Department of Medicine, Harvard Medical School, Director, Liver Cancer Research, Medicine, Massachusetts General Hospital, Discusses What Physicians Should Know About Sequencing TKIs In HCC. At The 2019 Gastrointestinal Cancers Symposium In San Francisco, CA On Jan 17, 2019. http://obroncology.com

Andrew X. Zhu, MD, PhD Associate Professor, Department of Medicine, Harvard Medical School, Director, Liver Cancer Research, Medicine, Massachusetts General Hospital, Discusses Checkpoint Inhibitors In Advanced HCC. At The 2019 Gastrointestinal Cancers Symposium In San Francisco, CA On Jan 17, 2019. http://obroncology.com

Andrew X. Zhu, MD, PhD Associate Professor, Department of Medicine, Harvard Medical School, Director, Liver Cancer Research, Medicine, Massachusetts General Hospital, Discusses Considering Whether Sorafenib Is Tolerable In Combination With I-O In HCC. At The 2019 Gastrointestinal Cancers Symposium In San Francisco, CA On Jan 17, 2019. http://obroncology.com

Richard Kim, MD, Gastrointestinal Oncology Department, Moffitt Cancer Center, Assistant Professor of Oncology, University of South Florida College of Medicine, discusses Targeted Therapies In Treatment Of Cholangiocarcinoma. At The 2019 Gastrointestinal Cancers Symposium In San Francisco, CA On Jan 17, 2019. http://obroncology.com

Richard Kim, MD, Gastrointestinal Oncology Department, Moffitt Cancer Center, Assistant Professor of Oncology, University of South Florida College of Medicine, discusses The Role Of BRAF Mutations In Treatment Of Cholangiocarcinoma. At The 2019 Gastrointestinal Cancers Symposium In San Francisco, CA On Jan 17, 2019. http://obroncology.com

Richard Kim, MD, Gastrointestinal Oncology Department, Moffitt Cancer Center, Assistant Professor of Oncology, University of South Florida College of Medicine, discusses How We Can Utilize TKIs In The Management Of Hepatocellular Carcinoma. At The 2019 Gastrointestinal Cancers Symposium In San Francisco, CA On Jan 17, 2019. http://obroncology.com

Richard Kim, MD, Gastrointestinal Oncology Department, Moffitt Cancer Center, Assistant Professor of Oncology, University of South Florida College of Medicine, discusses The Use Of Regorafenib In Treatment Of Colorectal Cancer. At The 2019 Gastrointestinal Cancers Symposium In San Francisco, CA On Jan 17, 2019. http://obroncology.com

Richard Finn, MD Professor of Clinical Medicine, Department of Medicine, Division of Hematology/ Oncology, Geffen School of Medicine, UCLA discusses Combined Checkpoint Inhibition In HCC & Biliary Tract Cancer. At The 2019 Gastrointestinal Cancers Symposium In San Francisco, CA On Jan 17, 2019. http://obroncology.com

Richard Finn, MD Professor of Clinical Medicine, Department of Medicine, Division of Hematology/ Oncology, Geffen School of Medicine, UCLA discusses Thoughts On The Role Of Systemic Therapy In HCC. At The 2019 Gastrointestinal Cancers Symposium In San Francisco, CA On Jan 17, 2019. http://obroncology.com

Dr. Jeffrey Bradley, Radiation Oncologist at Washington University in St. Louis, describes the use of stereotactic radiosurgery and stereotactic radiation therapy.

Dr. Jeffrey Bradley, Radiation Oncologist at Washington University in St. Louis, describes the history and current use of stereotactic radiation therapy for inoperable lung lesions.

Dr. Jeffrey Bradley, Radiation Oncologist at Washington University in St. Louis, defines oligometastatic lung cancer and describes the recent trend toward the use of stereotactic body radiation therapy to treat it.

Kathleen Mahoney, M.D. Instructor, Medicine, Harvard Medical School Discusses Protein Biomarkers, PD-L1, & Multifactorial. At the Seventeenth International Kidney Cancer Symposium on Nov 2, 2018.

Kathleen Mahoney, M.D. Instructor, Medicine, Harvard Medical School Discusses Is The Secreted Variant Of PD-L1 A Systemic Immunosuppressant. At the Seventeenth International Kidney Cancer Symposium on Nov 2, 2018.

Kathleen Mahoney, M.D. Instructor, Medicine, Harvard Medical School Discusses Data Regarding A Splice Variant Of PD-L1. At the Seventeenth International Kidney Cancer Symposium on Nov 2, 2018.

John Leppert, M.D., M.S. Associate Professor – Med Center Line, Urology At Stanford University Discusses Which Patient For Which Treatment. At the Seventeenth International Kidney Cancer Symposium on Nov 2, 2018.

John Leppert, M.D., M.S. Associate Professor – Med Center Line, Urology At Stanford University Discusses Over-Diagnosis & Over-Treatment Of Kidney Cancer. At the Seventeenth International Kidney Cancer Symposium on Nov 2, 2018.

John Leppert, M.D., M.S. Associate Professor – Med Center Line, Urology At Stanford University Discusses Increasing Awareness In Kidney Cancer. At the Seventeenth International Kidney Cancer Symposium on Nov 2, 2018.

John Leppert, M.D., M.S. Associate Professor – Med Center Line, Urology At Stanford University Discusses How To Better Treat Kidney Cancer. At the Seventeenth International Kidney Cancer Symposium on Nov 2, 2018.

Abhishek Tripathi, M.D. Assistant Professor Of Medicine In The Section Of Hematology/Oncology At Oklahoma Stephenson Cancer Center Discusses Adenosine Pathway Inhibitors In Kidney Cancer. At the Seventeenth International Kidney Cancer Symposium on Nov 2, 2018.

Steven Raman, M.D. Director of Prostate MR Imaging and Interventions and UCLA Prostate MR Imaging Research Group Discusses, MRPET & The Future Of Imaging. At the Seventeenth International Kidney Cancer Symposium on Nov 2, 2018.

Lisa X. Lee, M.D. Hematology/Oncology Specialist At University of California, Irvine Discusses, More Trials & Drugs Coming In 2019. At MOASC on Jan 19, 2019.

Lisa X. Lee, M.D. Hematology/Oncology Specialist At University of California, Irvine Discusses, How MAIA & FORTE Trials Effect Clinicians. At MOASC on Jan 19, 2019.

Lisa X. Lee, M.D. Hematology/Oncology Specialist At University of California, Irvine Discusses, Highlights Of MAIA, FORTE & Tourmaline MM-3 Trials. At MOASC on Jan 19, 2019.

Tsering Lama Tamang, M.D. Division of Hematology and Oncology, University of California, Irvine Discusses Data On The ALLIANCE Trial. At MOASC on Jan 19, 2019.

Tsering Lama Tamang, M.D. Division of Hematology and Oncology, University of California, Irvine Discusses ALLIANCE Trial & Low MRD. At MOASC on Jan 19, 2019.

Tsering Lama Tamang, M.D. Division of Hematology and Oncology, University of California, Irvine Discusses ALLIANCE Trial & Its Effect On Clinicians. At MOASC on Jan 19, 2019.

Tianyi Tang, M.D. Hematology/Oncology Fellow At University of California, Irvine Discusses How The MAIA Trial Will Effect Clinicians . At MOASC on Jan 19, 2019.

Tianyi Tang, M.D. Hematology/Oncology Fellow At University of California, Irvine Discusses Highlights Of The MAIA Trial. At MOASC on Jan 19, 2019.

Jamie Frediani, M.D. Board Certified Oncologist Who Provides Care For Pediatric Cancer Patients & Co-Director of AYA Program At CHOC Childrens Hospital Discusses Ruxolitinib Study & Communication. At MOASC on Jan 19, 2019.

Jamie Frediani, M.D. Board Certified Oncologist Who Provides Care For Pediatric Cancer Patients & Co-Director of AYA Program At CHOC Childrens Hospital Discusses Where Should AYA Patients Be Treated. At MOASC on Jan 19, 2019.

Jamie Frediani, M.D. Board Certified Oncologist Who Provides Care For Pediatric Cancer Patients & Co-Director of AYA Program At CHOC Childrens Hospital Discusses Improving The Treatment Of AYA Patients. At MOASC on Jan 19, 2019.

Jamie Frediani, M.D. Board Certified Oncologist Who Provides Care For Pediatric Cancer Patients & Co-Director of AYA Program At CHOC Childrens Hospital Discusses Clinical Trial Enrollment & ALL Mutations in AYA. At MOASC on Jan 19, 2019.

Jamie Frediani, M.D. Board Certified Oncologist Who Provides Care For Pediatric Cancer Patients & Co-Director of AYA Program At CHOC Childrens Hospital Discusses AYA Cancer Research & The Future. At MOASC on Jan 19, 2019.

Jamie Frediani, M.D. Board Certified Oncologist Who Provides Care For Pediatric Cancer Patients & Co-Director of AYA Program At CHOC Childrens Hospital Discusses Adolescent & Young Adult Oncology. At MOASC on Jan 19, 2019.

Elizabeth Brem, M.D. HS Clinical Assistant Professor at Chao Comprehensive Cancer Center Discusses Where We Are In Our Understanding Of DLBCL. At MOASC on Jan 19, 2019.

Elizabeth Brem, M.D. HS Clinical Assistant Professor at Chao Comprehensive Cancer Center Discusses Whats Next In DLBCL. At MOASC on Jan 19, 2019.

Elizabeth Brem, M.D. HS Clinical Assistant Professor at Chao Comprehensive Cancer Center Discusses Next Steps In R-CHOP Studies. At MOASC on Jan 19, 2019.

Elizabeth Brem, M.D. HS Clinical Assistant Professor at Chao Comprehensive Cancer Center Discusses Two Abstracts That Could Effect Clinicians. At MOASC on Jan 19, 2019.

Elizabeth Brem, M.D. HS Clinical Assistant Professor at Chao Comprehensive Cancer Center Discusses Four Abstracts Presented At MOASC. At MOASC on Jan 19, 2019.

Minh-Ha Tran, D.O. Associate Medical Director, Transfusion Medicine, Pathology at University of California Irvine Discusses Newer Agents Coming Out For TTP. At MOASC on Jan 19, 2019.

Minh-Ha Tran, D.O. Associate Medical Director, Transfusion Medicine, Pathology at University of California Irvine Discusses Updates On Thrombotic Microangiopathies. At MOASC on Jan 19, 2019.

Minh-Ha Tran, D.O. Associate Medical Director, Transfusion Medicine, Pathology at University of California Irvine Discusses Atypical Hemolytic Uremic Syndrome. At MOASC on Jan 19, 2019.

Minh-Ha Tran, D.O. Associate Medical Director, Transfusion Medicine, Pathology at University of California Irvine Discusses Data On TITAN Study & HERCULES Trial. At MOASC on Jan 19, 2019.

Deepa Jeyakumar, M.D. Assistant Clinical Professor, Division of Hematology/Oncology At University of California Irvine Discusses Three New Drugs Approved For AML. At MOASC on Jan 19, 2019.

Deepa Jeyakumar, M.D. Assistant Clinical Professor, Division of Hematology/Oncology At University of California Irvine Discusses Dosing Regarding Venetoclax. At MOASC on Jan 19, 2019.

Deepa Jeyakumar, M.D. Assistant Clinical Professor, Division of Hematology/Oncology At University of California Irvine Discusses Can Glasdegib Be Used As A Single Agent. At MOASC on Jan 19, 2019.

Tian Zhang, M.D. Medical Oncologist at Duke University specializing in caring for patients with genitourinary cancers, including kidney, bladder, prostate, and testicular cancers, Discusses PEDIGREE Trial & The Role It Plays In Kidney Cancer. At the Seventeenth International Kidney Cancer Symposium on Nov 2, 2018.

Tian Zhang, M.D. Medical Oncologist at Duke University specializing in caring for patients with genitourinary cancers, including kidney, bladder, prostate, and testicular cancers, Discusses PEDIGREE Trial Coming Early 2019. At the Seventeenth International Kidney Cancer Symposium on Nov 2, 2018.

Tian Zhang, M.D. Medical Oncologist at Duke University specializing in caring for patients with genitourinary cancers, including kidney, bladder, prostate, and testicular cancers, Discusses Discussing JAVELIN Renal 101 & KEYNOTE-426 Data. At the Seventeenth International Kidney Cancer Symposium on Nov 2, 2018.

Tian Zhang, M.D. Medical Oncologist at Duke University specializing in caring for patients with genitourinary cancers, including kidney, bladder, prostate, and testicular cancers, Discusses Data On PEDIGREE Trial For Kidney Cancer. At the Seventeenth International Kidney Cancer Symposium on Nov 2, 2018.

Tian Zhang, M.D. Medical Oncologist at Duke University specializing in caring for patients with genitourinary cancers, including kidney, bladder, prostate, and testicular cancers, Discusses CheckMate 214 Data Presentation. At the Seventeenth International Kidney Cancer Symposium on Nov 2, 2018.

Samra Turajlic, M.D. Consultant Medical Oncologist at The Royal Marsden NHS Foundation Trust, Discusses What To Achieve With The TRACERx Renal Study. At the Seventeenth International Kidney Cancer Symposium on Nov 2, 2018.

Samra Turajlic, M.D. Consultant Medical Oncologist at The Royal Marsden NHS Foundation Trust, Discusses Results From TRACERx Renal Study. At the Seventeenth International Kidney Cancer Symposium on Nov 2, 2018.

Samra Turajlic, M.D. Consultant Medical Oncologist at The Royal Marsden NHS Foundation Trust, Discusses The TRACERx Renal Study. At the Seventeenth International Kidney Cancer Symposium on Nov 2, 2018.

Brian Shuch, M.D. Associate Professor of Urology at UCLA Discusses, Tumor Enucleation Debate. At the Seventeenth International Kidney Cancer Symposium on Nov 2, 2018.

Brian Shuch, M.D. Associate Professor of Urology at UCLA Discusses, Overview of Sessions From KCA Miami. At the Seventeenth International Kidney Cancer Symposium on Nov 2, 2018.

Brian Shuch, M.D. Associate Professor of Urology at UCLA Discusses, Tumor Enucleation. At the Seventeenth International Kidney Cancer Symposium on Nov 2, 2018.

Brian Shuch, M.D. Associate Professor of Urology at UCLA Discusses, Benefits Of Tumor Enucleation. At the Seventeenth International Kidney Cancer Symposium on Nov 2, 2018.

Sumantra Kumar Pal, M.D. Assistant professor in the Department of Medical Oncology & Therapeutics Research and co-director of the Kidney Cancer Program at City of Hope, Discusses What Therapies Are To Come. At the Seventeenth International Kidney Cancer Symposium on Nov 2, 2018.

Sumantra Kumar Pal, M.D. Assistant professor in the Department of Medical Oncology & Therapeutics Research and co-director of the Kidney Cancer Program at City of Hope, Discusses Implementation Of Targeted Therapies In Front Line Setting. At the Seventeenth International Kidney Cancer Symposium on Nov 2, 2018.

Rana Mckay, M.D. Medical Oncologist, Assistant Professor of Medicine at The University Of California San Diego, discusses VEGF Plus Radium 223 Study Efficacy. At the Seventeenth International Kidney Cancer Symposium on Nov 2, 2018.

Rana Mckay, M.D. Medical Oncologist, Assistant Professor of Medicine at The University Of California San Diego, discusses Treating Patients With Bone Metastases. At the Seventeenth International Kidney Cancer Symposium on Nov 2, 2018.

Rana Mckay, M.D. Medical Oncologist, Assistant Professor of Medicine at The University Of California San Diego, discusses Study Involving VEGF-Targeted Therapy With Radium 223. At the Seventeenth International Kidney Cancer Symposium on Nov 2, 2018.

Charles Drake, M.D., PhD of Columbia University Medical Center, Discusses Upcoming Data Coming In 2019. At the Seventeenth International Kidney Cancer Symposium on Nov 2, 2018.

Charles Drake, M.D., PhD of Columbia University Medical Center, Discusses Profiling Tumor Microenvironment. At the Seventeenth International Kidney Cancer Symposium on Nov 2, 2018.

Charles Drake, M.D., PhD of Columbia University Medical Center, Discusses Next Gen Immune Activation In Kidney Cancer. At the Seventeenth International Kidney Cancer Symposium on Nov 2, 2018.

Charles Drake, M.D., PhD of Columbia University Medical Center, Discusses Figuring Out Best Drug Combo For Kidney Cancer. At the Seventeenth International Kidney Cancer Symposium on Nov 2, 2018.

Charles Drake, M.D., PhD of Columbia University Medical Center, Discusses Discussing Combining Drugs In Kidney Cancer. At the Seventeenth International Kidney Cancer Symposium on Nov 2, 2018.

Alexander Kutikov, M.D. Chief, Division of Urology and Urologic Oncology Professor At Fox Chase Cancer Center, Department of Surgical Oncology Kidney, Bladder, and Prostate Cancer TRDG Member, discusses Next Step In Tumor Resection. At the Seventeenth International Kidney Cancer Symposium on Nov 2, 2018.

Alexander Kutikov, M.D. Chief, Division of Urology and Urologic Oncology Professor At Fox Chase Cancer Center, Department of Surgical Oncology Kidney, Bladder, and Prostate Cancer TRDG Member, discusses Debate On Tumor Enucleation. At the Seventeenth International Kidney Cancer Symposium on Nov 2, 2018.

Charles Drake, M.D., PhD of Columbia University Medical Center, Discusses Making Immunotherapy Work Better For Kidney Cancer. At the Seventeenth International Kidney Cancer Symposium on Nov 2, 2018.

Robert Rifkin, MD, Hematologist/Oncologist, Associate Chair, US Oncology Hematology Research, Rocky Mountain Cancer Centers, discusses Can A Rituximab Biosimilar Replace Rituximab. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com

Peter Vorhees, MD, Director of Outreach and Clinical Operations, Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, discusses GRIFFIN Trial Safety & Efficacy. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com

Swaminathan P. Iyer, MD, Professor, Department of Lymphoma and Myeloma, Division of Cancer Medicine Division, MD Anderson Cancer Center, discusses Treatment Of T-Cell Compared To B-Cell Lymphoma. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com

Elizabeth Budde, MD, Assistant Professor in the Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, discusses CAR-T Therapy FDA Approvals. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com

Edward Copelan, MD, Chair, Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, discusses Molecular Profiling Of Patients. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com

Tatyana Feldman, MD, Hematology & Oncology, Hackensack University Medical Center, John Theurer Cancer Center, discusses Exciting Studies From ASH 2018 Regarding The Treatment Of PTCL. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com

Tatyana Feldman, MD, Hematology & Oncology, Hackensack University Medical Center, John Theurer Cancer Center, discusses ECHELON-2 Study. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com

Sen Zhuang, MD, PhD, VP, Oncology Clinical Research, Janssen, discusses Research & Development Philosophy At Janssen. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com

Sattva Neelapu, MD, Department of Lymphoma and Myeloma, Division of Cancer Medicines, MD Anderson Cancer Center, discusses Clinical Studies Examining Axicabtagene Ciloleucel. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com

Samer Khaled, MD, Assistant Clinical Professor, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, discusses MEDALIST Study. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com

Samer Khaled, MD, Assistant Clinical Professor, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, discusses Incorporating Venetoclax Into Treatment Regimens For AML. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com

Rod A. Humerickhouse, MD, PhD, Group Project Leader, Oncology Development, AbbVie, discusses Potential Side Effects From Venetoclax + Rituximab In CLL. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com

Rod A. Humerickhouse, MD, PhD, Group Project Leader, Oncology Development, AbbVie, discusses MRD As A Surrogate Marker In CLL. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com

Robert Rifkin, MD, Hematologist/Oncologist, Associate Chair, US Oncology Hematology Research, Rocky Mountain Cancer Centers, Discusses Clinical Data That Could Change The Way MM Is Treated. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com

Ravi Vij, MD, Professor of Medicine, Oncology Division, Bone Marrow Transplantation & Leukemia, Washington University School of Medicine, discusses Molecular Testing & AML. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com

Ravi Vij, MD, Professor of Medicine, Oncology Division, Bone Marrow Transplantation & Leukemia, Washington University School of Medicine, discusses Current Maintenance Regimens For MM. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com

Rafael Fonseca, MD, Hematologist, Mayo Clinic, discusses Frontline MM Treatment Patterns. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com

Rafael Fonseca, MD, Hematologist, Mayo Clinic, discusses TOURMALINE-MM3 Study In MM. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com

Nikhil Munshi, MD, Director of Basic and Correlative Science, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Professor of Medicine, Harvard Medical School, discusses POLLUX & CASTOR Studies Regarding The Use Of Daratumumab. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com

Nikhil Munshi, MD, Director of Basic and Correlative Science, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Professor of Medicine, Harvard Medical School, discusses Outcomes Of The CA204-142 Study. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com

John Burke, MD, Hematologist/Oncologist and Associate Chair of the US Oncology Hematology Research Program, Rocky Mountain Cancer Centers, discusses Beat AML Umbrella Study. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com

John Burke, MD, Hematologist/Oncologist and Associate Chair of the US Oncology Hematology Research Program, Rocky Mountain Cancer Centers, discusses Gilteritinib In AML Treatment. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com

Jeff Sharman, MD, Director of Research, Willamette Valley Cancer Institute, Medical Director of Hematology Research, The US Oncology Network, discusses Phase 3 Study Investigating Ibrutinib In Older CLL Patients. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com

Jeff Sharman, MD, Director of Research, Willamette Valley Cancer Institute, Medical Director of Hematology Research, The US Oncology Network, discusses Outcomes Of CAPTIVATE Study. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com

Jasmine Zain, MD, Associate Clinical Professor of Hematology & Hematopoietic Cell Transplantation, Director, T Cell Lymphoma Program, City of Hope, discusses Standard Of Care In Treatment Of PTCL. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com

Jasmine Zain, MD, Associate Clinical Professor of Hematology & Hematopoietic Cell Transplantation, Director, T Cell Lymphoma Program, City of Hope, discusses Successful Induction Regimens When Treating PTCL. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com

Frederick Locke, MD, Program Co-Leader, Immunology Moffitt Cancer Center, discusses Improvements To Turn Around Time With CAR-T Therapies. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com

Frederick Locke, MD, Program Co-Leader, Immunology Moffitt Cancer Center, discusses How To Integrate CAR-T With Stem Cell Transplant. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com

Chadi Nabhan, MD, MBA, VP, Chief Medical Officer, Cardinal Health Specialty Solutions, discusses Skepticism Regarding MACRA. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com

Chadi Nabhan, MD, MBA, VP, Chief Medical Officer, Cardinal Health Specialty Solutions, discusses Key Factors Contributing To Physician Burnout. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com

Carol Moreno, MD, PhD, Hematologist, University of Barcelona, discusses Outcomes Of The illUMINTATE Trial. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com

Andre Goy, MD, Chairman and Director of John Theurer Cancer Center, Chief of the Division of Lymphoma, Hackensack University Medical Center, Discusses The Use Of Axi-Cel CAR-T Cell Therapy In DLBCL. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com

Andre Goy, MD, Chairman and Director of John Theurer Cancer Center, Chief of the Division of Lymphoma, Hackensack University Medical Center, discusses Checkpoint Inhibitors In Hematologic Malignancies. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com

Sundar Jagannath, MD, Professor of Medicine, Hematology and Medical Oncology, Mount Sinai School of Medicine, Discusses The Role Of Checkpoint Inhibitors In Treatment Of MM. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com

Sundar Jagannath, MD, Professor of Medicine, Hematology and Medical Oncology, Mount Sinai School of Medicine, discusses Proteasome Inhibitors In The Treatment Of MM. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com

Elizabeth Budde, MD, Assistant Professor in the Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, discusses The Clinical Study Investigating Mosunetuzumab. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com       car t cell therapy,  city of hope, mosunetuzumab

Julie Vose, MD, Professor, Internal Medicine Division of Oncology & Hematology University of Nebraska Medical Center, discusses Results Of The AUGMENT Study In Relapsed/Refractory Indolent NHL. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com

Julie Vose, MD, Professor, Internal Medicine Division of Oncology & Hematology University of Nebraska Medical Center, Discusses Improvements Made In The Delivery Of CAR-T Therapies. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com

Robert Rifkin, MD, Hematologist/Oncologist, Associate Chair, US Oncology Hematology Research, Rocky Mountain Cancer Centers, discusses Outcomes Of The TOURMALINE-MM3 Study. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com

Jasmine Zain, MD, Associate Clinical Professor of Hematology & Hematopoietic Cell Transplantation, Director, T cell Lymphoma Program, City of Hope, discusses Most Exciting Studies In Lymphoma. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com

Andre Goy, MD, Chairman and Director of John Theurer Cancer Center, Chief of the Division of Lymphoma, Hackensack University Medical Center, discusses Responses & Outcomes When Treating Lymphoma With CAR-T Therapies. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com

Ravi Vij, MD, Professor of Medicine, Oncology Division, Bone Marrow Transplantation & Leukemia, Washington University School of Medicine, discusses The POLLUX & CASTOR Clinical Studies. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com

Tatyana Feldman, MD, Hematology & Oncology, Hackensack University Medical Center, John Theurer Cancer Center, discusses Improvements In The Treatment Of CTCL. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com

Robert Rifkin, MD, Hematologist/Oncologist, Associate Chair, US Oncology Hematology Research, Rocky Mountain Cancer Centers, discusses The Rationale For Genetically Profiling AML Patients. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com

Rod A. Humerickhouse, MD, PhD, Group Project Leader, Oncology Development, AbbVie, discusses Testing For Minimal Residual Disease In CLL. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com

Keith Pratz, MD, Assistant Professor of Oncology, Sidney Kimmel, Comprehensive Cancer Center, Johns Hopkins University, Discusses Phase I Study Of Gilteritinib. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com

Keith Pratz, MD, Assistant Professor of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, discusses Reliability Of The Companion Diagnostic Test For FLT3. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com

Swaminathan P. Iyer, MD, Professor, Department of Lymphoma and Myeloma, Division of Cancer Medicine Division, MD Anderson Cancer Center, Discusses Improvements In The Treatment Of CTCL. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com

Andrzej Jakubowiak, MD, Professor of Medicine Director, Myeloma Program, University of Chicago Medical Center, discusses Thoughts On The POLLUX & CASTOR Studies. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com

Andrzej Jakubowiak, MD, Professor of Medicine Director, Myeloma Program, University of Chicago Medical Center, discusses ALCYONE Trial. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com

James McCloskey, MD, Interim Chief, Division of Leukemia, Hackensack University Medical Center, John Theurer Cancer Center, discusses Reliability Of The Companion Diagnostic Test For FLT3. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com

James McCloskey, MD, Interim Chief, Division of Leukemia, Hackensack University Medical Center, John Theurer Cancer Center, discusses Molecular Testing In AML. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com

David Siegel, MD, Hematologist/Oncologist, Hackensack University Medical Center, John Theurer Cancer Center, discusses TOURMALINE-MM3 Study And The Treatment Of MM. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com

David Siegel, MD, Hematologist/Oncologist, Hackensack University Medical Center, John Theurer Cancer Center, discusses Thoughts On The Daratumamab Studies. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com

John Burke, MD, Hematologist/Oncologist and Associate Chair of the US Oncology Hematology Research Program, Rocky Mountain Cancer Centers, discusses Incorporation Of Venetoclax Into AML Treatment. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com

Jeff Sharman, MD, Director of Research, Willamette Valley Cancer Institute, Medical Director of Hematology Research, The US Oncology Network, Discusses Phase 3 Study Investigating Ibrutinib In Younger CLL Patients. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com

Lorenz Trumper, MD, Professor of Internal Medicine and Chairman of the Department of Hematology and Oncology, Georg August University of Göttingen, discusses The Current Standard Of Care For The Frontline Treatment Of PTCL. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com

Lorenz Trumper, MD, Professor of Internal Medicine and Chairman of the Department of Hematology and Oncology, Georg August University of Göttingen, discusses What Differeniates Brentuximab Vedotin From Other Treatment Options. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com

Maria-Victoria Mateos, MD, Associate Professor of Medicine, University of Salamanca, discusses TOURMALINE-MM3 Study. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com

Ravi Vij, MD, Professor of Medicine, Oncology Division, Bone Marrow Transplantation & Leukemia, Washington University School of Medicine, discusses Anti-BCMA CAR-T Cell Therapy In MM. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com

James McCloskey, MD, Interim Chief, Division of Leukemia, Hackensack University Medical Center, John Theurer Cancer Center, discusses How The FLT3 Mutation Influences Treatment Decisions In AML. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com

Jeff Sharman, MD, Director of Research, Willamette Valley Cancer Institute, Medical Director of Hematology Research, The US Oncology Network, discusses Rituximab Biosimilars In Follicular Lymphoma. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com

Carol Moreno, MD, PhD, Hematologist, University of Barcelona, discusses Phase 3 Trial Examining Ibrutinib + Rituximab Versus FCR. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com

Swaminathan P. Iyer, MD, Professor, Department of Lymphoma and Myeloma, Division of Cancer Medicine Division, MD Anderson Cancer Center, discusses Outcomes Of The ECHELON-2 Study. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com

Keith Pratz, MD Assistant Professor of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, discusses Emerging Therapies For Newly Diagnosed Or Relapsed AML Patients. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com

Maria-Victoria Mateos, MD, Associate Professor of Medicine, University of Salamanca, discusses Outcomes From The ALCYONE Study. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com

Sen Zhuang, MD, PhD, VP, Oncology Clinical Research, Janssen, discusses The Development Of LCAR-B38M. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com

Tatyana Feldman, MD, Hematology & Oncology, Hackensack University Medical Center, John Theurer Cancer Center, discusses Outcomes Of The ECHELON-2 Study. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com

Sattva Neelapu, MD, Department of Lymphoma and Myeloma, Division of Cancer Medicines, MD Anderson Cancer Center, discusses The Use Of Axicabtagene Ciloleucel With Elderly Lymphoma Patients. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com

Rod A. Humerickhouse, MD, PhD, Group Project Leader, Oncology Development, AbbVie, discusses Treating CLL Patients With Venetoclax And Rituximab. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com

Keith Pratz, MD, Assistant Professor of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, discusses Venetoclax In Treatment Of AML. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com

Peter Vorhees, MD, Director of Outreach and Clinical Operations, Department of Hematologic Oncology and Blood Diosrders, Levine Cancer Institute, discusses Outcomes Of The TOURMALINE-MM3 Study. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com

Andre Goy, MD, Chairman and Director of John Theurer Cancer Center, Chief of the Division of Lymphoma, Hackensack University Medical Center, discusses Immunotherapy And The Treatment Of Hematologic Malignancies. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com

Jasmine Zain, MD, Associate Clinical Professor of Hematology & Hematopoietic Cell Transplantation, Director, T cell Lymphoma Program, City of Hope, discusses The Impact Of The New Induction Regimen In PTCL. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com

Chadi Nabhan, MD, MBA, VP, Chief Medical Officer, Cardinal Health Specialty Solutions, discusses The Role Of Advanced Practice Practitioners. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com